Showing results (131-140 of 188) with videos related to
Sort By:
Pageof 19
JAMA Network Open|August 21, 2025
Allostatic Load and Racial and Rural Disparities in Breast Cancer SurvivalYufan Guan, Roger T Anderson, Supraja Gururaj, et al.Blood|March 18, 2010
AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated KitTzu-Yin Lin, Joelle Fenger, Sridhar Murahari, et al.Annals of Surgical Oncology|May 1, 1996
Complications of mastectomy and their relationship to biopsy techniqueK A Lipshy, J P Neifeld, R M Boyle, et al.Breast Cancer Research and Treatment|July 14, 2011
A gene transcription signature of obesity in breast cancerChad J Creighton, Yvonne H Sada, Yiqun Zhang, et al.Journal of Leukocyte Biology|March 2, 2016
Tumor-reactive immune cells protect against metastatic tumor and induce immunoediting of indolent but not quiescent tumor cellsKyle K Payne, Rebecca C Keim, Laura Graham, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2003
The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27Harry D Bear, Stewart Anderson, Ann Brown, et al.Breast Cancer Research and Treatment|November 8, 2013
Peripheral blood mononuclear cells of patients with breast cancer can be reprogrammed to enhance anti-HER-2/neu reactivity and overcome myeloid-derived suppressor cellsKyle K Payne, Christine K Zoon, Wen Wan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2012
Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27Eleftherios P Mamounas, Stewart J Anderson, James J Dignam, et al.BMC Cancer|October 12, 2016
MiR-9 is overexpressed in spontaneous canine osteosarcoma and promotes a metastatic phenotype including invasion and migration in osteoblasts and osteosarcoma cell linesJoelle M Fenger, Ryan D Roberts, O Hans Iwenofu, et al.American Journal of Clinical Oncology|October 1, 1994
The efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte macrophage colony-stimulating factor in permitting the administration of higher doses of cyclophosphamide in a doxorubicin-cyclophosphamide combination. An NSABP pilot study in patients with metastatic or high-risk primary breast cancer. National Surgical Adjuvant Breast and Bowel ProjectE P Mamounas, S Anderson, D L Wickerham, et al.Pageof 19